patients was HCV eradicated, because, in the remain-weakly positive) before therapy have a high rate of sustained response when treated with interferon, in der, HCV RNA was apparently negative from the beginning. Thus, cure was achieved with the aggressive our experience, these patients do not show
Prevalence and prediction of osteopenia in chronic liver disease
β Scribed by Herbert L. Bonkovsky; Michael Hawkins; Karen Steinberg; Theodore Hersh; John T. Galambos; J. Michael Henderson; William J. Millikan; John R. Galloway
- Publisher
- John Wiley and Sons
- Year
- 1990
- Tongue
- English
- Weight
- 729 KB
- Volume
- 12
- Category
- Article
- ISSN
- 0270-9139
No coin nor oath required. For personal study only.
β¦ Synopsis
To obtain information on the prevalence and clinical and laboratory correlates of osteopenia in patients with chronic liver disease, we measured bone densities and 30 selected laboratory variables in 133 subjects (70 men, 63 women) with liver disease. Thirty-two had alcoholic liver disease, 18 had primary biliary cirrhosis, 16 had primary sclerosing cholangitis, 48 had other forms of cirrhosis (cryptogenic, posthepatitic) and 19 had chronic hepatitis or fibrosis without cir- rhosis. Bone densities of the lumbar spine and three sites of the proximal femur (neck, Ward's triangle, greater trochanter) were estimated by dual-photon absorptiometry. Bone densities at all Sites were mgflcantly correlated to one another (r = 0.4 to 0.g; 96% confidence intervals = 0.24-0.64 to 0.81-0.90; p < 0.0001 for all). Compared with an age-and gendermatched reference group, patients with liver disease had highly significant decreases in bone densities ( > 2 standard deviations below control values; p c 0.0008 at all sites). Decreases were particularly marked (24% to 42%) at Ward's triangle, the site of the femoral neck particularly prone to fracture. The prevalence of decreased bone densities ranged from 10% to 66%, depending on the site studied and the nature of the liver disease. Among 30 laboratory variables studied, there were significant (p < 0.05) correlations with bone densities at more than one Site for urinary creatinine (r = 0.21,0.26), urinary calcium (r = -0.18, -0.23), serum total alkaline phosphatase (r = -0.18, -0.27) and the liver-1 isozyme of serum alkaline phosphatase (r = -0.19, -0.26). We conclude that osteopenia is prevalent in patients with chronic liver disease, particularly in those with reduced skeletal muscle mass (reflected in lower creatinine excretions) and higher serum alkaline phosphatases. However,
π SIMILAR VOLUMES
## Abstract To evaluate the prevalence of hepatitis C virus infection in northwest China, 179 chronic liver disease patients in this area were examined for antibody to hepatitis C virus core protein (antiβHCVcore). This antibody was found in only 5 (14 percent) of 37 chronic nonβA, nonβB liver dise
To investigate the prevalence and incidence of cholecystolithiasis in hepatitis B surface antigen-positive chronic liver diseases, a prospective study using hepatobiliary ultrasonography was conducted in 933 "healthy" persons and four groups of HBsAg-positive patients: 226 asymptomatic carriers, 73
## Abstract A serological survey for hepatitis B, C, and D markers was carried out in the Yemen Republic. Serum samples from 243 pregnant females, 294 male blood donors, and 108 patients with chronic liver disease were examined. Hepatitis B surface antigen (HBsAg) was found in 18.5% healthy individ
Data on the prevalence of chronic liver disease, derived from selected series of hospitalized patients or from mortality registers, underestimate the prevalence of chronic liver disease. The Dionysos Study is a cohort study that investigated for the first time the prevalence of chronic liver disease